Catalist-listed Clearbridge Health has launched its adult immune cell banking business, targeting Southeast Asia and Hong Kong as primary markets.
The business is operated through Clearbridge’s wholly-owned subsidiary Cell Entrust Bio Co, based in Hong Kong. The cell banking service enables individuals to collect and store their own peripheral blood mononuclear cells (PBMCs) for future treatments such as cellular therapies for cancer and other conditions.
Clearbridge explains that it has adopted an asset-light approach by partnering exclusively with a locally licensed and AABB-accredited biobank in Hong Kong, a strategic move to enable immediate revenue generating business and saving lead time than establishing its own
greenfield laboratory facility.
This exclusivity agreement grants the group commercial rights to the biobanking services in Hong Kong, Macau, and the broader Greater Bay Area, in addition to Southeast Asia markets.
Clearbridge expects this new business to address a market void by offering scalable, consumer-oriented PBMCs banking services that existing providers in Asia do not sufficiently or actively cover.
This business is designed to be scalable and revenue-generating from the outset, whilst strengthening our position across the cellular therapy value chain. We are building a company with diversified revenue streams and meaningful exposure to high growth areas of precision medicine, underpinned by our debt-free balance sheet and disciplined operational approach,” says Jeremy Yee, executive director and CEO of Clearbridge Health.
See also: Newly-configured board of Fu Yu Corp fires CEO Seow for 'gross default and misconduct'
Shares in Clearbridge Health closed flat at 0.2 cents on Nov 3.
